In this study, Cloudpharm participated in a study for the discovery of novel agents bearing different scaffolds which may evolve as a new class of AT1 receptor antagonists. Nowadays, AT1 receptor (AT1R) antagonists (ARBs) constitute the one of the most prevalent...
Cloudpharm has recently joined the Hellenic Bio Cluster (HBio, www.hbio.gr). HBio supports and promotes the Greek life sciences and healthcare ecosystem. It is the first biosciences cluster in Greece bringing together the innovation leaders of Greece in the sectors of...
